Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against <i>HER2-</i>positive advanced gastric cancer (AGC). However, data on its real-world efficacy in AGC patients are insufficient, and the predictive marker of T-DXd is unclear. In this multi-center retrospective study, we c...
Main Authors: | Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Shogen Boku, Nobuhiro Shibata, Hiroki Nagai, Takanobu Shimada, Takao Tsuduki, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/8/2247 |
Similar Items
-
HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01) -
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice
by: Giulia Notini, et al.
Published: (2024-03-01) -
Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer
by: Hiroaki Yamane, et al.
Published: (2024-03-01) -
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
by: Jan-Willem Henning, et al.
Published: (2023-08-01) -
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
by: Chiaki Matsui, et al.
Published: (2023-07-01)